Sydney and Brisbane-based ams has been described by its new owners as “the leading independent analytical and cGMP Quality Control (QC) services provider for biopharmaceutical products and medical devices in Australia,” and will give Eurofins a strong entry platform for its own biopharmaceutical testing capabilities in the Asia-Pacific region.
“The acquisition of ams Laboratories provides Eurofins a platform to deploy its renowned capabilities in biopharmaceutical products testing in the Asia Pacific region, and reinforces the Group's global leadership in the biopharmaceutical products testing market,” said Eurofins CEO Gilles Martin.
“We look forward to expanding and strengthening ams Laboratories' footprint by providing them access to the full range of Eurofins' capabilities.”
The Australian firm generated revenues of over €5m ($6m) last year - the majority from biopharmaceutical products testing - and currently employs 45 staff across its two sites.
The acquisition is Eurofins’ second so far this year, after buying another QC testing firm – Sinensis Life Science BV – in January to further expand its global reach, and continues an M&A strategy which defined 2015 for the firm.
In June last year Eurofins announced it would pay $40m (€35m) for a 75% stake in Emory Genetics Laboratory (EGL) – a specialist provider of genetic testing service – in a deal with current owner Emory University's School of Medicine.
A week earlier the firm bought French testing services firm Biomnis from Bio Alfras SAS for €220m ($249m) and two weeks after it announced a €150m investment in lab group BioAccess.
And a month before that Eurofins acquired US-based testing services specialist Diatherix Laboratories.